EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vitamin K3 (Menadione) Targets TBK1 to Enhance the Efficacy of Pirfenidone in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis

Yanan Wang, Junxian Cao, Yingxin Zhou, Xuxia Cao, Shiwen Deng iD, Yu Li, Caifeng Li, Shihuan Tang, Peng Chen

International Journal of Molecular Sciences · 30.10.2026 · 27 (21) · 9739

DOI: 10.3390/ijms27219739 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.10.2026. Verfasst von Yanan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical…. Hauptthemen laut MEDLINE: Bleomycin, Pyridones, Protein Serine-Threonine Kinases, Vitamin K 3. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Academy of Chinese Medical Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible interstitial lung disease. Current antifibrotic drugs, exemplified by pirfenidone (PFD), only slow disease progression with limited efficacy and adverse effects, underscoring the need for novel therapeutic strategies. By integrating single-cell transcriptomics with the Drug2Cell algorithm, we performed drug prioritization at single-cell resolution and identified menadione (vitamin K3, VK3), a synthetic naphthoquinone and the minimal core of naturally occurring vitamin K, as a candidate preferentially active in alveolar epithelial cells. In bleomycin (BLM)-stimulated A549 cells and a mouse model of pulmonary fibrosis, therapeutic co-administration of low-dose VK3 and PFD reduced vimentin expression by 44.8% and collagen deposition by 50.3%, and decreased fibroblast abundance by 36.7%, thereby attenuating histopathological damage and restoring BLM-disrupted alveolar epithelial homeostasis. Experiments with VK3 alone further demonstrated that its antifibrotic activity is independent of conversion to vitamin K2. Mechanistically, thermal proteome profiling identified TANK-binding kinase 1 (TBK1) as the principal candidate target; molecular docking and molecular dynamics simulations predicted a stable binding mode, independently confirmed by biolayer interferometry and differential scanning fluorimetry, demonstrating direct binding of VK3 to TBK1 with nanomolar affinity. TBK1 knockdown suppressed BLM-induced fibrotic responses, establishing TBK1 as a positive regulator of pulmonary fibrosis. In vitro signaling analysis revealed that VK3 plus PFD inhibits phosphorylation of TBK1 and STAT3, whereas PFD alone reduces phosphorylation of JAK1 and STAT3, suggesting that both agents converge on STAT3 through distinct upstream nodes. Although VK3 exhibits dose-dependent cytotoxicity precluding direct clinical use as monotherapy, its validated high-affinity target TBK1 and privileged naphthoquinone scaffold lay a rational foundation for lead optimization toward safer anti-IPF agents, and its ability to enhance PFD efficacy supports further development as an adjunct to existing antifibrotic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BleomycinPyridonesProtein Serine-Threonine KinasesVitamin K 3Pulmonary FibrosisIdiopathic Pulmonary FibrosisAnimalsHumansMiceDisease Models, AnimalA549 CellsMolecular Docking SimulationMaleAntifibrotic AgentsMice, Inbred C57BL

Stichwörter der Autor:innen

STAT3 signalingTBK1bleomycinidiopathic pulmonary fibrosismouse modelnaphthoquinonepirfenidonepulmonary fibrosisvitamin K3

Substanzen

BleomycinpirfenidonePyridonesProtein Serine-Threonine KinasesVitamin K 3Antifibrotic Agents

Autor:innen und Institutionen

  • State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
  • Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang 330115, China.

ORCID-Profile: Shiwen Deng

Förderung

  • China Academy of Chinese Medical Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Wang, Y., Cao, J., Zhou, Y., Cao, X., Deng, S., Li, Y., Li, C., Tang, S., & Chen, P. (2026). Vitamin K3 (Menadione) Targets TBK1 to Enhance the Efficacy of Pirfenidone in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis. International Journal of Molecular Sciences, 27(21), 9739. https://doi.org/10.3390/ijms27219739

Vancouver

Wang Y, Cao J, Zhou Y, Cao X, Deng S, Li Y, et al. Vitamin K3 (Menadione) Targets TBK1 to Enhance the Efficacy of Pirfenidone in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis. International Journal of Molecular Sciences. 2026;27(21):9739. doi:10.3390/ijms27219739

BibTeX
@article{Wang2026,
  author = {Wang, Yanan and Cao, Junxian and Zhou, Yingxin and Cao, Xuxia and Deng, Shiwen and Li, Yu and Li, Caifeng and Tang, Shihuan and Chen, Peng},
  title = {Vitamin K3 (Menadione) Targets TBK1 to Enhance the Efficacy of Pirfenidone in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9739},
  doi = {10.3390/ijms27219739}
}
Kostenlos starten →